Throughout the last three months, 10 analysts have evaluated Edwards Lifesciences EW, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $96.0, a high estimate of $105.00, and a low estimate of $83.00. This upward trend is apparent, with the current average reflecting a 11.34% increase from the previous average price target of $86.22.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Edwards Lifesciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anthony Petrone | Mizuho | Raises | Buy | $105.00 | $95.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $92.00 | $86.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $98.00 | $90.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $103.00 | $95.00 |
| Suraj Kalia | Oppenheimer | Raises | Outperform | $100.00 | $93.00 |
| Rick Wise | Stifel | Raises | Hold | $83.00 | $70.00 |
| Patrick Wood | Morgan Stanley | Raises | Overweight | $95.00 | $80.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $95.00 | $82.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $95.00 | $85.00 |
| Larry Biegelsen | Wells Fargo | Announces | Overweight | $94.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Edwards Lifesciences's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Edwards Lifesciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Unveiling the Story Behind Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Breaking Down Edwards Lifesciences's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Edwards Lifesciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 13.78%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of 24.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Edwards Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of 5.56%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Edwards Lifesciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
